The nice people at “Transfusion News” sent their update
today. I was a tad vague on what the first article was about, but the article
on the use of convalescent plasma was intriguing, if only because opinion seems
to be utterly divided on the matter right now…
RBCeq: A Novel, User-Friendly, Algorithm for Genetic Blood Typing |
 January 26, 2022
About
85 million units of red blood cells (RBCs) are transfused globally, and
some patients requiring multiple transfusions are at a high risk of
alloimmunization. Currently, serology is the gold standard for RBC
phenotyping and matching. Recently, molecular methods utilizing DNA
microarrays and single nucleotide polymorphism (SNP) genotyping have
enabled large-scale typing, but these methods are incapable of
identifying novel blood groups. [Read More]
|
|
|
Covid 19 Convalescent Plasma in the Omicron Era |
 Join
Transfusion News Associate Editors Daniela Hermelin MD and Monica
Pagano MD on Twitter Space this Friday January 28 from 11:00-11:30 AM
EST for the first ever #Blooducation Baristas live event. Dr. Hermelin
and Dr. Pagano will be serving up piping hot Transfusion News along with
Evan Bloch MD, Claudia Cohn MD, and BJ Grossman MD. [Set a reminder to join us]
|
|
Variable Transfusion Practices for Bleeding ICU Patients Globally |
 January 19, 2022
Approximately
40-50% of patients in the intensive care unit (ICU) receive blood
transfusions. Many studies have focused on bleeding in trauma patients
who are usually healthy. Patients in the ICU, however, more often have
multiple comorbidities and may require a more nuanced transfusion
approach. [Read More]
|
|
Plasma Exchange for Hypertriglyceridemic Acute Pancreatitis |
 January 11, 2022
Acute
pancreatitis can be caused by many etiologies including high levels of
plasma triglycerides. Hypertriglyceridemic acute pancreatitis (HTGAP)
can cause life-threatening complications such as multi-organ failure.
While plasma exchange is used to quickly lower plasma triglyceride
concentrations, the benefits of this treatment are not clear. [Read More]
|
No comments:
Post a Comment